- Home
- BTBT vs ZNTL Comparison
BTBT vs ZNTL Comparison
Compare BTBT & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BTBT | ZNTL |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 118.3M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BTBT | ZNTL |
|---|---|---|
| Price | $2.04 | $1.36 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $6.50 | $5.87 |
| AVG Volume (30 Days) | ★ 28.0M | 788.8K |
| Earning Date | 11-14-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ $105,703,143.00 | $26,865,000.00 |
| Revenue This Year | $7.15 | N/A |
| Revenue Next Year | $90.95 | N/A |
| P/E Ratio | $3.29 | ★ N/A |
| Revenue Growth | ★ 7.86 | N/A |
| 52 Week Low | $1.69 | $1.01 |
| 52 Week High | $4.55 | $3.33 |
Technical Indicators
Market Signals| Indicator | BTBT | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 42.20 | 46.71 |
| Support Level | $1.86 | $1.31 |
| Resistance Level | $2.35 | $1.46 |
| Average True Range (ATR) | 0.14 | 0.06 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 29.03 | 29.41 |
Price Performance
Historical ComparisonAbout BTBT Bit Digital Inc.
Bit Digital Inc is engaged in the Bitcoin mining business, Ethereum staking activities and specialized cloud-infrastructure services for artificial intelligence applications through its wholly owned subsidiaries. Its mining platform operates with the primary intent of accumulating bitcoin which may sell for fiat currency from time to time depending on market conditions. The Company has four reportable segments: digital asset mining, cloud services, colocation services, and ETH Staking. It generates majority of its revenue from digital asset mining.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.